SubsidieMeestersDirect Selective Laser Trabeculoplasty (DSLT): Accessible glaucoma care in seconds
BELKIN Vision's Direct Selective Laser Trabeculoplasty (DSLT) aims to revolutionize glaucoma treatment with an automated, non-contact device that simplifies the procedure for widespread use.
Projectdetails
Introduction
Our novel laser technology - Direct Selective Laser Trabeculoplasty (DSLT) is an automated laser procedure for accessible primary treatment of glaucoma and ocular hypertension. Our Eagle™ device has the potential to revolutionize glaucoma care as it is non-contact, intuitive, and quick.
Technology Overview
The technology is ground-breaking, as the procedure doesn’t require expertise and involves simply pressing a button and delivering treatment in seconds. DSLT technology is poised to achieve widespread acceptance, as it is not limited to glaucoma specialists, or bound to glaucoma medication compliance.
Clinical Support
In addition, our technology is supported by promising First-in-Human clinical trial results as well as the expertise and guidance of key opinion leaders in the field of ophthalmology.
Funding and Commercialization
EIC funding will support BELKIN Laser (re-branded recently as BELKIN Vision) in commercializing this sight-saving technology by establishing the commercial value chain, market launch, and scale-up.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 6.589.750 |
Tijdlijn
| Startdatum | 1-1-2022 |
| Einddatum | 31-12-2022 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- BELKIN VISION LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry. | EIC Accelerator | € 2.497.469 | 2022 | Details |
New era of guided lens implantation in cataract surgeryAkknaTek's imaging technology enhances cataract surgery by ensuring precise lens placement through a comprehensive three-module system for pre-operative screening, real-time monitoring, and post-operative adjustments. | EIC Accelerator | € 2.289.875 | 2023 | Details |
Laser bioprinting device and in vivo applicationsPhosPrint's D-LIB platform uses a laser bioprinter for precise in-vivo tissue printing, aiming to enhance surgical outcomes in bladder cancer patients through real-time tissue engineering. | EIC Accelerator | € 2.000.560 | 2023 | Details |
INNOVATIVE SOLUTION OF ELECTRO-FOCUS EYEGLASSESLaclarée is developing adaptive autofocus eyeglasses with variable fluidic lenses to provide real-time vision correction for presbyopia, enhancing comfort and clarity for users. | EIC Accelerator | € 2.499.999 | 2024 | Details |
.lumen - Empowering the blindLumen aims to enhance mobility for the visually impaired with an affordable device that navigates environments using sound and sensory feedback, seeking EUR 5.5M for final product development and market entry. | EIC Accelerator | € 2.165.828 | 2022 | Details |
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry.
New era of guided lens implantation in cataract surgery
AkknaTek's imaging technology enhances cataract surgery by ensuring precise lens placement through a comprehensive three-module system for pre-operative screening, real-time monitoring, and post-operative adjustments.
Laser bioprinting device and in vivo applications
PhosPrint's D-LIB platform uses a laser bioprinter for precise in-vivo tissue printing, aiming to enhance surgical outcomes in bladder cancer patients through real-time tissue engineering.
INNOVATIVE SOLUTION OF ELECTRO-FOCUS EYEGLASSES
Laclarée is developing adaptive autofocus eyeglasses with variable fluidic lenses to provide real-time vision correction for presbyopia, enhancing comfort and clarity for users.
.lumen - Empowering the blind
Lumen aims to enhance mobility for the visually impaired with an affordable device that navigates environments using sound and sensory feedback, seeking EUR 5.5M for final product development and market entry.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Pulsed Laser Light and Nano-encapsulated Ocular Dyes for Advanced Therapies in the EyeDYE-LIGHT aims to enhance ocular drug delivery and safety by utilizing low-energy pulsed-lasers with nano-encapsulated dyes to facilitate targeted treatment of severe ocular diseases. | ERC Starting... | € 1.499.351 | 2023 | Details |
SIGHT: Scientific and Innovative Glaucoma Healthcare TechnologiesHet SIGHT-project ontwikkelt een innovatief implantaat om glaucoom te behandelen en blindheid te voorkomen. | 1.1 - Het ve... | € 483.538 | 2024 | Details |
Next Generation Glioma Treatments using Direct Light TherapyGlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers. | EIC Pathfinder | € 2.219.087 | 2024 | Details |
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENTMULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care. | EIC Pathfinder | € 2.863.733 | 2024 | Details |
Optical imaging platform for high-throughput longitudinal studies of the eye in disease modelsThe OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use. | ERC Proof of... | € 150.000 | 2023 | Details |
Pulsed Laser Light and Nano-encapsulated Ocular Dyes for Advanced Therapies in the Eye
DYE-LIGHT aims to enhance ocular drug delivery and safety by utilizing low-energy pulsed-lasers with nano-encapsulated dyes to facilitate targeted treatment of severe ocular diseases.
SIGHT: Scientific and Innovative Glaucoma Healthcare Technologies
Het SIGHT-project ontwikkelt een innovatief implantaat om glaucoom te behandelen en blindheid te voorkomen.
Next Generation Glioma Treatments using Direct Light Therapy
GlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers.
MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT
MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.
Optical imaging platform for high-throughput longitudinal studies of the eye in disease models
The OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use.